Metastatic hormone-sensitive prostate cancer: lines of therapy
5 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Fit | Triplet therapy, high volume, fit for chemotherapy | Androgen deprivation plus docetaxel plus darolutamide (ARASENS) or abiraterone (PEACE-1). | NCCN Guidelines: Prostate Cancer | 96 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | All patients, backbone | Continuous androgen deprivation with a GnRH agonist, GnRH antagonist or orchiectomy; never alone in fit men. | NCCN Guidelines: Prostate Cancer | 95 | |
| All comers | Doublet therapy | Androgen deprivation plus abiraterone (LATITUDE, STAMPEDE), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN) or darolutamide (ARANOTE). | NCCN Guidelines: Prostate Cancer | 95 | |
| All comers | Low-volume disease | Doublet therapy plus radiotherapy to the prostate (STAMPEDE); metastasis-directed radiotherapy within trials. | NCCN Guidelines: Prostate Cancer | 93 | |
| All comers | Biomarker-selected additions (2026) | Capivasertib with abiraterone for PTEN-deficient tumours (CAPItello-281); 177Lu-PSMA-617 with androgen receptor pathway inhibitor for PSMA-positive disease (PSMAddition). | 94 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.